Abstract. Adrenal insufficiency can result from primary disorder of the adrenal gland or occurs secondarily due to deficiency in adrenocorticotropic hormone (ACTH) or corticotropin-releasing hormone (CRH). To prevent adrenal crisis, it is thus important to test the remaining function of the adrenal gland. Tests for the function of the hypothalamicpituitary-adrenal (HPA) axis are also useful for examining localization of disease causing adrenal insufficiency. Generally, the insulin tolerance test (ITT) is useful for examining the HPA axis in both hypothalamic and pituitary diseases; however, ITT has a number of disadvantages. The growth hormone-releasing peptide (GHRP)-2 test may be a useful tool for diagnosing secondary adrenal insufficiency such as hypothalamic disorder and pituitary damage. In the present study, we examined the diagnostic usefulness of the GHRP-2 test as a substitute for ITT in hypopituitarism. We showed that patients with significant ACTH response to ITT also had significant response to the GHRP-2 test, while patients with no significant ACTH response to ITT also had no significant response to the GHRP-2 test. These data suggest that the GHRP-2 test may be a useful diagnostic tool for secondary adrenal insufficiency such as hypothalamic disorder and pituitary damage.
ADRENAL insufficiency can result from primary disorder of the adrenal gland or occurs secondarily due to deficiency in adrenocorticotropic hormone (ACTH) or corticotropin-releasing hormone (CRH) [1] . An elevated ACTH level accompanied by an inappropriately low serum cortisol level suggests primary adrenal insufficiency or adrenal insensitivity to ACTH. However, in mild cases of primary adrenal insufficiency, serum cortisol levels are sometimes within lower normal levels. To prevent adrenal crisis, it is therefore important to test the remaining function of the adrenal gland. Tests for the function of the hypothalamicpituitary-adrenal axis (HPA) are also useful for examining localization of the disease causing adrenal insufficiency [2] .
The CRH test and insulin tolerance test (ITT) are both useful for diagnosing the disease causing adrenal insufficiency, such as hypothalamic disorder or pituitary damage. Insulin-induced hypoglycemic stress stimulates CRH production in the hypothalamic paraventricular nucleus (PVN) of the brain [3, 4, 5] , and secretion of CRH to the pituitary portal circulation to induce ACTH release from the anterior pituitary (AP) [4] . ACTH in turn stimulates glucocorticoid release from the adrenal gland. Therefore, ITT is useful for examining the HPA axis in both hypothalamic and pituitary diseases; however, ITT has a number of disadvantages [6, 7] . Hypoglycemia persists longer in patients with severe hypopituitarism and in the elderly.
Elderly patients with hyperthyroidism and hypokalemia should be observed carefully when inducing hypoglycemia. Furthermore, hypoglycemia induction is contraindicated in patients with coronary or cerebrovascular disease, a history of ischemic heart disease or any convulsive disease [6] .
Growth hormone (GH)-releasing peptides (GHRPs) are synthetic peptides inducing strong GH release in both animals and humans [8] . Among them, GHRP-6 has been extensively studied in humans [8] . GHRP-2 is one of the most potent GHRPs and acts via a specific receptor, in which ghrelin would be a natural ligand [9] . GHRPs or ghrelin also stimulates ACTH release via CRH and/or arginine vasopressin (AVP) in the hypothalamus [10, 11] . Among them, GHRP-2 is currently and clinically available in Japan, and may be useful for diagnosing secondary adrenal insufficiency such as hypothalamic disorder and pituitary damage [7] . In the present study, we examined the diagnostic usefulness of the GHRP-2 test as a substitute for ITT in hypopituitarism.
Patients and Methods

Patients
A total of 9 patients (4 women and 5 men) referred to our department for further evaluation of pituitary hormones were followed-up using the CRH test, ITT, and GHRP-2 test to examine and evaluate ACTH secretory dynamics. Each test was performed under treatment with 0.25 mg dexamethasone in cases 1, 2, 4, 6, 7, and 9. Written informed consent was obtained before commencing the study, and all tests were performed according to clinical guidelines.
Clinical summary
Case 1: A man was diagnosed as having hypophysitis accompanied by diabetes insipidus and hypopituitarism at the age of 43. He was initially treated with replacement of hydrocortisone and desmopressin acetate, and the dose of desmopressin was gradually tapered over a two-year period. He was referred to our department for re-evaluation of pituitary function.
Case 2: A woman was diagnosed as having lymphocytic hypophysitis accompanied by diabetes insipidus and hypopituitarism at the age of 36. She has been treated with replacement of hydrocortisone and desmopressin acetate. She was referred to our department for re-evaluation of pituitary function.
Case 3: A 62-year-old man was referred to our department for re-evaluation of pituitary tumor. On the basis of a diagnosis of non-functioning pituitary adenoma, resection of the pituitary adenoma was imperfectly performed at the age of 44. This diagnosis was subsequently confirmed by immunohistochemistry. However, the residual tumor has been grown up after the operation.
Case 4: A 53-year-old woman was referred to our department for evaluation and treatment of unconsciousness. At the age of 49 she had been diagnosed as having chronic thyroiditis. She was diagnosed as having secondary adrenal failure in ACTH deficiency after the examination.
Case 5: A 42-year-old woman was diagnosed as having lymphocytic hypophysitis accompanied by diabetes insipidus and hypopituitarism. She was treated with replacement of hydrocortisone, levothyroxin, and desmopressin acetate after the examination.
Case 6: A 76-year-old woman was referred to our department for evaluation and treatment of unconsciousness. She was diagnosed as having secondary adrenal failure in ACTH deficiency after the examination.
Case 7: A 46-year-old man was referred to our department for evaluation and treatment of unconsciousness. She was diagnosed as having secondary adrenal failure in ACTH deficiency after the examination.
Case 8: A 16-year-old man was referred to our department for evaluation of growth. He was diagnosed as having delayed puberty after the examination.
Case 9: A 56-year-old woman was referred to our department for re-evaluation of pituitary function after operation. On the basis of a diagnosis of non-functioning pituitary adenoma, resection of the pituitary adenoma was performed at the age of 50 and 56. This diagnosis was subsequently confirmed by immunohistochemistry. She has been treated with replacement of hydrocortisone and levothyroxin after the first operation because of hypopituitarism. Her pituitary function was re-evaluated after the second operation.
Adrenocorticotropic hormone provocative test
Corticotropin-releasing hormone test
A single dose (100 µg) of CRH was intravenously injected into each subject under fasting condition. Blood samples were taken before and 30, 60, 90, and 120 min after injecting CRH, and then plasma ACTH level was determined. More than 2-fold increase in the ACTH level compared with the basal level was considered as a significant response.
Insulin tolerance test
After overnight fasting, regular insulin was injected intravenously at 0.5 U/kg body weight. Blood samples were taken before and 30, 60, and 90 min after the injection, and then plasma ACTH level was determined. More than 2-fold increase in the ACTH level compared with the basal level was considered a significant response.
Growth hormone (GH)-releasing peptide-2 test
A single dose (100 µg) of GHRP-2 was intravenously injected into each subject under fasting condition. Blood samples were taken before and 15, 30, 45, and 60 min after injecting GHRP-2, and then plasma ACTH level was determined.
Assays
Plasma ACTH level was measured by immunoradiometric assay (IRMA) using an assay kit (ACTH IRMA kit, Mitsubishi Kagaku Iatron, Tokyo, Japan).
Results
Patient characteristics
The characteristics of the 9 patients are shown in Table 1 . The results of the hormonal data (except ACTH and cortisol) following GHRH/TRH/CRH/ LHRH test are listed in Table 2 . The 9 patients included 4 males and 5 females, with ages ranging from 16 to 76 years. Four patients with panhypopituitarism, 3 with ACTH-isolated deficiency, and 1 with non-functioning adenoma, and delayed puberty, were enrolled in the study. In 6 of the 9 patients, plasma ACTH levels were significantly increased following the CRH test, while that in the remaining 3 patients were also increased following ITT.
Adrenocorticotropic hormone response to growth hormone (GH)-releasing peptide-2
Since GHRP-2 induces ACTH secretion in normal subjects, the effect of GHRP-2 on ACTH level was therefore examined in the patients. More than 2-fold increase in the ACTH level compared with the basal level was considered as a significant response. Mild flashing and sweating were transiently observed in the patients after GHRP-2 injection, but disappeared within 1 hour. Patients with no significant response to ITT also showed no significant response to the GHRP-2 test (Table 1) . Patients with significant response to ITT also had significant response to the GHRP-2 test, although changes in plasma ACTH level were variable following GHRP-2 injection. In case 3, considerable increase in plasma ACTH level was observed following ITT, while a significant but small increase in ACTH level was found after the GHRP-2 test (Fig. 1) . In cases 5 and 8, plasma ACTH level were markedly increased following the GHRP-2 test compared with ITT ( Fig. 1) .
Discussion
In the present study, we showed that patients with significant ACTH response to ITT also showed significant response to the GHRP-2 test, while patients with no significant ACTH response to ITT also had no significant response to the GHRP-2 test. GHRP-2 stimulates GH release by acting at both hypothalamic and pituitary sites [12] , and also induces ACTH release in humans [13] . Hirotani et al. reported that intravenous administration of GHRP-2 increased plasma ACTH level, but did not stimulate ACTH release from rat primary pituitary cells [14] . The present data suggest that GHRP-2 acts via the hypothalamus to stimulate ACTH release. Therefore, the mechanism of the GHRP-2 test would be similar to that of ITT regarding induction of ACTH release.
Changes in plasma ACTH level were variable following GHRP-2 injection. For example, in a case with non-functioning adenoma, considerable increase in plasma ACTH level was shown following ITT, while a significant but small increase in ACTH level was found following the GHRP-2 test (Fig. 1) . In a case with panhypopituitarism and delayed puberty, plasma ACTH level was markedly increased following the GHRP-2 test compared with ITT. The mechanisms underlying these differences remain unclear.
In fact, insulin administered in the ITT acts via the hypothalamus to stimulate ACTH release by inducing the release of both CRH and AVP. Stress-induced intracellular cyclic AMP production is involved in stimulating the transcription of both CRH and AVP genes at least via the protein kinase A pathway in the hypothalamus [15] . CRH and AVP neurons in the parvocellular region of PVN project to the external zone of the median eminence [16, 17] . Furthermore, CRH and AVP in parvocellular PVN neurons exert synergistic effects on ACTH secretion from the AP [18, 19] . Therefore, ITT-induced stress hormones would contribute to stress responses through stimulation of CRH and AVP neurons of the hypothalamus, causing ACTH secretion.
On the other hand, the mechanism of how GHRPs stimulate ACTH secretion remains controversial. Ghrelin, an endogenous GHRP-receptor ligand, increases release of CRH and AVP from the hypothalamus [10] . The combination of GHRP, hexarelin, and the AVP analogue desmopressin does not increase plasma ACTH level compared with hexarelin alone [11] , suggesting the effects of GHRPs on ACTH release via AVP production. Conversely, another study demonstrated that the combination of GHRP-2 and AVP induced a more pronounced increase in the ACTH level than that of GHRP-2 and CRH [14] . A CRH antagonist markedly inhibited GHRP-2-induced ACTH release in conscious rats, whereas an AVP antagonist or anti-AVP antiserum did not [14] . These findings therefore suggest that GHRP-2 may act via the hypothalamus to stimulate more extensive ACTH release than AVP, mainly by inducing CRH release.
For the diagnosis of ACTH deficiency, the CRH test and ITT have been frequently used. More than 1.5-fold increase or an increment of 50 pg/ml of the ACTH level compared with the basal level is generally considered a significant response. Although ITT is useful for examining the HPA axis in both hypothalamic and pituitary diseases, ITT has a number of disadvantages. The GHRP-2 test as an alternative would be useful for the diagnosis of hypopituitarism. Although more than 2-fold increase in the ACTH level was considered a significant response in the present study, further research is necessary to establish consistency with the ITT results.
Additionally, reproducibility of the ACTH response and effects of gender, age, and adiposity should also be considered. For example, age-related variations reduce the GH responses to GHRP [20] . It is possible that ACTH responses to GHRP-2 are also decreased in aging. Replacement therapy may affect on the ACTH responses. The effect of a synthetic GHRP on ACTH was abolished by 1 mg of dexamethasone in human [21] . Thyroid hormones may influence GHRPinduced ACTH secretion, as shown in GH secretion [22]. Although desmopressin may stimulate ACTH secretion in Cushing's disease [23] , it is unclear that it modifies ACTH response to GHRP in healthy humans. These effects should be examined in a large-scale study.
In conclusion, we reported the diagnostic usefulness of the GHRP-2 test as a substitute for ITT in hypopituitarism. Patients with significant ACTH response to ITT also showed significant response to the GHRP-2 test, while patients with no significant ACTH response to ITT also had no significant response to the GHRP-2 test. Thus, the GHRP-2 test may be a useful diagnostic tool for secondary adrenal insufficiency such as hypothalamic disorder and pituitary damage.
